Prognostic and clinicopathological value of systemic immune-inflammation index in patients with osteosarcoma: a meta-analysis
View abstract on PubMed
Summary
This summary is machine-generated.The systemic immune-inflammation index (SII) is a significant predictor of poor prognosis in osteosarcoma (OSA) patients, correlating with reduced overall survival and advanced Enneking stage. This finding aids in understanding OSA patient outcomes.
Area Of Science
- Oncology
- Immunology
- Biostatistics
Background
- Osteosarcoma (OSA) prognosis prediction requires reliable biomarkers.
- The prognostic value of the systemic immune-inflammation index (SII) in OSA remains inconsistent.
- This meta-analysis aims to clarify the precise prognostic role of SII in OSA.
Approach
- A systematic literature search was conducted across major databases (PubMed, Embase, Web of Science, Cochrane Library, CNKI) up to February 24, 2024.
- Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess SII's predictive efficiency.
- Correlation analysis between SII and clinicopathological characteristics of OSA was performed.
Key Points
- Six studies encompassing 1015 OSA patients were included.
- Elevated SII was significantly associated with poorer overall survival (OS) (HR=2.01, p=0.002).
- Higher SII levels correlated with advanced Enneking stage III (OR=2.21, p=0.024) but not with other clinicopathological factors.
Conclusions
- The systemic immune-inflammation index (SII) serves as a valuable prognostic indicator in osteosarcoma.
- Higher SII is markedly linked to adverse outcomes, including reduced overall survival and advanced disease stage.
- Further research may explore incorporating SII into clinical decision-making for OSA patients.

